<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hum Genet</journal-id><journal-title>Journal of Human Genetics</journal-title><issn pub-type="ppub">1434-5161</issn><issn pub-type="epub">1435-232X</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17479212</article-id><article-id pub-id-type="publisher-id">147</article-id><article-id pub-id-type="doi">10.1007/s10038-007-0147-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The 894G&#x0003e;T variant in the endothelial nitric oxide synthase gene and spina bifida risk</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>van der Linden</surname><given-names>Ivon J. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heil</surname><given-names>Sandra G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>den Heijer</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Blom</surname><given-names>Henk J.</given-names></name><address><phone>+31-20-4442881</phone><fax>+31-20-4440305</fax><email>h.blom@vumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Laboratory of Pediatrics and Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Endocrinology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Epidemiology and Biostatistics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands </aff><aff id="Aff4"><label>4</label>Metabolic Unit, PK 1-X-018, Department of Clinical Chemistry, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>5</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><volume>52</volume><issue>6</issue><fpage>516</fpage><lpage>520</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; The Japan Society of Human Genetics and Springer 2007</copyright-statement></permissions><abstract><p>The 894G&#x0003e;T single nucleotide polymorphism (SNP) in the endothelial NOS (<italic>NOS3</italic>) gene, has recently been associated with embryonic spina bifida risk. In this study, a possible association between the <italic>NOS3</italic> 894G&#x0003e;T SNP and spina bifida risk in both mothers and children in a Dutch population was examined using both a case-control design and a transmission disequilibrium test (TDT). Possible interactions between the <italic>NOS3</italic> 894G&#x0003e;T SNP and the <italic>MTHFR</italic> 677C&#x0003e;T SNP, elevated plasma homocysteine, and decreased plasma folate concentrations were also studied. The <italic>NOS3</italic> 894TT genotype did not increase spina bifida risk in mothers or children (OR 1.50, 95%CI 0.71&#x02013;3.19 and OR 1.78, 95%CI 0.75&#x02013;4.25, respectively). The TDT demonstrated no preferential transmission of the <italic>NOS3</italic> 894T allele (<italic>&#x003a7;</italic><sup>2</sup>&#x000a0;=&#x000a0;0.06, <italic>P</italic>&#x000a0;=&#x000a0;0.81). In combination with the <italic>MTHFR</italic> 677TT genotype or elevated plasma homocysteine concentrations, the <italic>NOS3</italic> 894GT/TT genotype increased maternal spina bifida risk (OR 4.52, 95%CI 1.55&#x02013;13.22 and OR 3.38, 95%CI 1.46&#x02013;7.84, respectively). In our study population, the <italic>NOS3</italic> 894GT/TT genotype might be a risk factor for having a spina bifida affected child in mothers who already have an impaired homocysteine metabolism.</p></abstract><kwd-group><title>Keywords</title><kwd><italic>NOS3</italic> 894G&#x0003e;T</kwd><kwd>Spina bifida</kwd><kwd>Transmission disequilibrium test</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Japan Society of Human Genetics and Springer 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Nitric oxide synthase (NOS) catalyzes the generation of nitric oxide (NO), an important signaling molecule that mediates many of its biological effects by activating the enzyme guanylyl cyclase, thereby increasing cyclic GMP synthesis (Murad <xref ref-type="bibr" rid="CR9">2006</xref>). Besides its important role in cardiovascular control, NO has been suggested to play a role in development (Lee and Juchau <xref ref-type="bibr" rid="CR8">1994</xref>). NO has been demonstrated to be present in the neural tube of chick embryos at the time of neurulation (Traister et al. <xref ref-type="bibr" rid="CR19">2002</xref>) and regulates the balance between mitosis and programmed cell death (Plachta et al. <xref ref-type="bibr" rid="CR11">2003</xref>). Other studies show that NO can inhibit methionine synthase (MTR) enzyme activity, thereby interfering with homocysteine remethylation (Danishpajooh et al. <xref ref-type="bibr" rid="CR3">2001</xref>) and proper neurulation (Nachmany et al. <xref ref-type="bibr" rid="CR10">2006</xref>; Weil et al. <xref ref-type="bibr" rid="CR22">2004</xref>).</p><p>The 894G&#x0003e;T single nucleotide polymorphism (SNP) in the endothelial-derived nitric oxide synthase (<italic>NOS3</italic>) gene, identified by Hingorani et al. (<xref ref-type="bibr" rid="CR7">1999</xref>), was shown to be associated with elevated plasma homocysteine levels in nonsmokers with low serum folate concentrations (Brown et al. <xref ref-type="bibr" rid="CR2">2003</xref>). More recently, it was demonstrated that the <italic>NOS3</italic> 894GT genotype is an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09&#x02013;2.42) (Brown et al. <xref ref-type="bibr" rid="CR1">2004</xref>).</p><p>In this study, we examined the relation between the <italic>NOS3</italic> 894G&#x0003e;T SNP and spina bifida risk in both mothers and children using a case-control design and a transmission disequilibrium test (TDT). An effect of the <italic>NOS3</italic> 894G&#x0003e;T SNP on plasma homocysteine or plasma folate concentration was examined as well as possible interactions between the <italic>NOS3</italic> 894G&#x0003e;T SNP and the <italic>MTHFR</italic> 677C&#x0003e;T SNP, elevated plasma homocysteine, and decreased plasma folate concentrations.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Study population</title><p>The study population has been described in detail before (van der Linden et al. <xref ref-type="bibr" rid="CR21">2006</xref>). Briefly, the study population was recruited in collaboration with the BOSK and was extended by a group from the Pediatric Neurology Department of the Radboud University Nijmegen Medical Center. The study group included 109 spina bifida patients (61 girls and 48 boys, mean age 16.4&#x000a0;&#x000b1;&#x000a0;11.3), their mothers (<italic>n</italic>&#x000a0;=&#x000a0;121, mean age 42.9&#x000a0;&#x000b1;&#x000a0;10.9) and fathers (<italic>n</italic>&#x000a0;=&#x000a0;103, mean age 44.9&#x000a0;&#x000b1;&#x000a0;10.2).</p><p>The control group consisted of 500 volunteers recruited from a general practice in The Hague (den Heijer et al. <xref ref-type="bibr" rid="CR4">1995</xref>). In the present study we only included the 292 women from this control group (mean age 50.6&#x000a0;&#x000b1;&#x000a0;13.5). The pediatric control group included 234 children (119 girls and 115 boys, mean age 8.4&#x000a0;&#x000b1;&#x000a0;6.4) (van Beynum et al. <xref ref-type="bibr" rid="CR20">1999</xref>). The children of secondary school age were healthy volunteers, and the younger children were, for ethical reasons, recruited in a hospital setting. The local medical ethics committee approved the study.</p><p>For the present study, DNA of 102 spina bifida patients, 116 mothers, 101 fathers, 265 control women and 211 pediatric controls was available for genotyping.</p></sec><sec id="Sec4"><title>Biochemical determinations</title><p>Plasma total homocysteine concentration was measured in EDTA plasma by HPLC and fluorescence detection, as previously described by te Poele-Pothoff et al. (<xref ref-type="bibr" rid="CR16">1995</xref>).</p><p>Plasma folate concentration was determined using the Dualcount Solid Phase Boil Radio assay (Diagnostic Product Corporation, Los Angeles, CA).</p></sec><sec id="Sec5"><title>PCR amplification and genotype determination</title><p><italic>NOS3</italic> 894G&#x0003e;T genotyping was performed according to Hingorani et al. (<xref ref-type="bibr" rid="CR7">1999</xref>). Primer annealing took place at a temperature of 58&#x000b0;C. The PCR product of 206&#x000a0;bp was cut with the restriction enzyme <italic>Mbo</italic>I, which cuts the T allele in fragments of 119 and 87&#x000a0;bp.</p></sec><sec id="Sec6"><title>Statistical analyses</title><sec id="Sec7"><title>Case-control study</title><p>Odds ratios (ORs) and their 95% confidence intervals (95%CI) were calculated by means of logistic regression analysis.</p><p>The effect of the <italic>NOS3</italic> 894G&#x0003e;T SNP on plasma homocysteine and plasma folate concentration was studied by means of linear regression analysis. Since the distributions of plasma homocysteine and plasma folate concentrations are positively skewed, these variables were logarithmically transformed prior to linear regression analysis.</p><p>Deviation from Hardy&#x02013;Weinberg equilibrium was calculated to assess the accuracy of the genotyping assay.</p><p>The power of the case-control study was calculated using the Genetic Power Calculator (Purcell et al. <xref ref-type="bibr" rid="CR12">2003</xref>). All tests were performed using SPSS software package version 12.0.1. Statistical significance was accepted at a two-tailed <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 or 95%CI of an odds ratio that did not include 1.0.</p></sec><sec id="Sec8"><title>Transmission disequilibrium test</title><p>The relation between the <italic>NOS3</italic> 894G&#x0003e;T genotype of the spina bifida patients and spina bifida risk was assessed by evaluating the transmission of alleles from heterozygous parents to their affected offspring using the TDT, a family-based association test (Spielman et al. <xref ref-type="bibr" rid="CR14">1993</xref>). The power of the TDT was calculated using the Genetic Power Calculator (Purcell et al. <xref ref-type="bibr" rid="CR12">2003</xref>).</p></sec></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Case-control study</title><p>The <italic>NOS3</italic> 894G&#x0003e;T genotype could be determined in 115 mothers of a spina bifida affected child and in 259 female controls. Genotype distribution did not differ from that expected under Hardy&#x02013;Weinberg equilibrium (<italic>P</italic>&#x000a0;=&#x000a0;0.83), and the power to detect a twofold increase in maternal spina bifida risk was 59%. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> demonstrates that neither the <italic>NOS3</italic> 894GT genotype nor the <italic>NOS3</italic> 894TT genotype increased maternal spina bifida risk relative to the <italic>NOS3</italic> 894GG genotype. Since the effect of the <italic>NOS3</italic> 894GT genotype and the <italic>NOS3</italic> 894TT genotype on spina bifida risk was the same relative to the <italic>NOS3</italic> 894GG genotype, the <italic>NOS3</italic> 894GT and TT genotypes were combined to increase power, which resulted in a nonsignificant 36% increased risk of having a spina bifida affected child relative to the <italic>NOS3</italic> 894GG genotype (OR 1.36, 95%CI 0.87&#x02013;2.11). The <italic>NOS3</italic> 894G&#x0003e;T SNP was not associated with plasma homocysteine or plasma folate concentrations in mothers and female controls (data not shown). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>The <italic>NOS3</italic> 894G&#x0003e;T genotype distribution and unadjusted ORs in mothers of a spina bifida affected child and female controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&#x0003e;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">49 (42.6)</td><td align="left">130 (50.2)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">53 (46.1)</td><td align="left">106 (40.9)</td><td align="left">1.33 (0.83&#x02013;2.11)</td></tr><tr><td align="left">TT</td><td align="left">13 (11.3)</td><td align="left">23 (8.9)</td><td align="left">1.50 (0.71&#x02013;3.19)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap></p><p>In 95 spina bifida patients and 207 pediatric controls, <italic>NOS3</italic> 894G&#x0003e;T genotyping was performed successfully. The <italic>NOS3</italic> 894G&#x0003e;T genotype distribution did not differ from that expected under Hardy&#x02013;Weinberg equilibrium (<italic>P</italic>&#x000a0;=&#x000a0;0.76), and the power of the study was 51%. The <italic>NOS3</italic> 894GT genotype increased spina bifida risk in children whereas the <italic>NOS3</italic> 894TT genotype did not (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Combining the <italic>NOS3</italic> 894GT and 894TT genotypes resulted in a 66% increase in spina bifida risk relative to the <italic>NOS3</italic> 894GG genotype (OR 1.66, 95%CI 1.02&#x02013;2.72). In the pediatric controls, the <italic>NOS3</italic> 894GT and 894TT genotypes were associated with increased plasma homocysteine concentrations relative to the <italic>NOS3</italic> 894GG genotype (14.7% increase, 95%CI 4.2&#x02013;26.2% and 23.5% increase, 95%CI 3.9&#x02013;46.8%, respectively). There was no association between the <italic>NOS3</italic> 894G&#x0003e;T SNP and plasma folate concentration in children (data not shown). <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>The <italic>NOS3</italic> 894G&#x0003e;T genotype distribution and unadjusted ORs in spina bifida patients and pediatric controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&#x0003e;T</th><th align="left">SB patients (%)</th><th align="left">Pediatric controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">39 (41.1)</td><td align="left">111 (53.6)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GT</td><td align="left">46 (48.4)</td><td align="left">80 (38.6)</td><td align="left">1.64 (0.98&#x02013;2.74)</td></tr><tr><td align="left">TT</td><td align="left">10 (10.5)</td><td align="left">16 (7.7)</td><td align="left">1.78 (0.75&#x02013;4.25)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Transmission disequilibrium test</title><p>In this study there were 75 complete mother&#x02013;father&#x02013;child triads, and the power to detect a twofold increase in spina bifida risk was 32%. In 36 out of 70 informative transmissions (51.4%), the <italic>NOS3</italic> 894T allele was transmitted to the child, which resulted in a <italic>&#x003a7;</italic><sup>2</sup> of 0.06 (<italic>P</italic>&#x000a0;=&#x000a0;0.81).</p></sec><sec id="Sec12"><title>Gene-gene interaction</title><p>Data on both the <italic>NOS3</italic> 894G&#x0003e;T genotype and the <italic>MTHFR</italic> 677C&#x0003e;T genotype were present for 110 mothers of a spina bifida affected child and 259 control women. Since the <italic>MTHFR</italic> 677CT genotype did not increase spina bifida risk relative to the <italic>MTHFR</italic> 677CC genotype, we decided to combine the <italic>MTHFR</italic> 677CC and CT genotypes to increase power. In combination with the <italic>MTHFR</italic> 677TT genotype, the <italic>NOS3</italic> 894GT/TT genotype increased the risk of having spina bifida affected offspring 4.5 times relative to the <italic>NOS3</italic> 894GG genotype combined with the <italic>MTHFR</italic> 677CC/CT genotype (OR 4.52, 95%CI 1.55&#x02013;13.22) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). <table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&#x0003e;T SNP and the <italic>MTHFR</italic> 677C&#x0003e;T SNP</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&#x0003e;T</th><th align="left"><italic>MTHFR</italic> 677C&#x0003e;T</th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">CC/CT</td><td align="left">42 (38.2)</td><td align="left">114 (44.0)</td><td align="left">1<sup>a</sup></td></tr><tr><td align="left">GG</td><td align="left">TT</td><td align="left">6 (5.5)</td><td align="left">16 (6.2)</td><td align="left">1.02 (0.37&#x02013;2.77)</td></tr><tr><td align="left">GT/TT</td><td align="left">CC/CT</td><td align="left">52 (47.3)</td><td align="left">123 (47.5)</td><td align="left">1.15 (0.71&#x02013;1.85)</td></tr><tr><td align="left">GT/TT</td><td align="left">TT</td><td align="left">10 (9.1)</td><td align="left">6 (2.3)</td><td align="left">4.52 (1.55&#x02013;13.22)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Reference group</p></table-wrap-foot></table-wrap></p><p>In children, there was no interaction between the <italic>NOS3</italic> 894GT/TT genotype and the <italic>MTHFR</italic> 677TT genotype (OR 1.23, 95%CI 0.31&#x02013;4.91) (data not shown).</p></sec><sec id="Sec13"><title>Gene-metabolite interactions</title><p>Since the <italic>MTHFR</italic> 677C&#x0003e;T SNP is a genetic determinant of plasma folate and plasma homocysteine concentrations, possible interactions between the <italic>NOS3</italic> 894G&#x0003e;T SNP and these metabolites were examined in mothers. In combination with decreased plasma folate concentrations (&#x0003c;8.52&#x000a0;nmol/L), the <italic>NOS3</italic> 894GT/TT genotype did not increase maternal spina bifida risk relative to the <italic>NOS3</italic> 894GG genotype in combination with normal plasma folate concentrations (&#x02265;8.52&#x000a0;nmol/L) (OR 1.14, 95%CI 0.49&#x02013;2.67) (data not shown). The risk of having spina bifida affected offspring increased to 3.4-fold when the <italic>NOS3</italic> 894GT/TT genotype was present in combination with elevated plasma homocysteine concentrations (&#x02265;12.56&#x000a0;&#x003bc;mol/L) (OR 3.38, 95%CI 1.46&#x02013;7.84) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). <table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Maternal spina bifida risk for the combination of the <italic>NOS3</italic> 894G&#x0003e;T SNP and elevated plasma homocysteine concentration, adjusted for age</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>NOS3</italic> 894G&#x0003e;T</th><th align="left">Plasma Hcy conc (&#x003bc;mol/L)<sup>a</sup></th><th align="left">Mothers (%)</th><th align="left">Female controls (%)</th><th align="left">OR (95%CI)</th></tr></thead><tbody><tr><td align="left">GG</td><td align="left">&#x0003c;12.56</td><td align="left">42 (36.8)</td><td align="left">100 (38.6)</td><td align="left">1<sup>b</sup></td></tr><tr><td align="left">GG</td><td align="left">&#x02265;12.56</td><td align="left">7 (6.1)</td><td align="left">30 (11.6)</td><td align="left">0.66 (0.26&#x02013;1.65)</td></tr><tr><td align="left">GT/TT</td><td align="left">&#x0003c;12.56</td><td align="left">47 (41.2)</td><td align="left">108 (41.7)</td><td align="left">1.17 (0.69&#x02013;1.96)</td></tr><tr><td align="left">GT/TT</td><td align="left">&#x02265;12.56</td><td align="left">18 (15.8)</td><td align="left">21 (8.1)</td><td align="left">3.38 (1.46&#x02013;7.84)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The 80th percentile of the control plasma homocysteine distribution was used to define elevated plasma homocysteine concentrations</p><p><sup>b</sup>Reference group</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>In this study, the <italic>NOS3</italic> 894TT genotype did not significantly increase spina bifida risk, and the TDT demonstrated no preferential transmission of the <italic>NOS3</italic> 894T allele. However, in combination with the <italic>MTHFR</italic> 677TT genotype or elevated plasma homocysteine concentrations, the <italic>NOS3</italic> 894GT/TT genotype increased maternal spina bifida risk 4.5- and 3.4-fold, respectively.</p><p>Using a likelihood ratio test (LRT) for both proband and mother trios, Brown et al. (<xref ref-type="bibr" rid="CR1">2004</xref>) demonstrated the <italic>NOS3</italic> 894GT genotype, but not the <italic>NOS3</italic> 894TT genotype, to be an embryonic risk factor for spina bifida (OR 1.63, 95%CI 1.09&#x02013;2.42). Data from our case-control study might be in line with this observation of Brown et al. (<xref ref-type="bibr" rid="CR1">2004</xref>); however, based on the effect of the heterozygous <italic>NOS3</italic> 894GT genotype on spina bifida risk, a larger effect of the <italic>NOS3</italic> 894TT genotype on spina bifida risk would be expected. The observation that the <italic>NOS3</italic> 894GT genotype increases spina bifida risk and the <italic>NOS3</italic> 894TT genotype does not could be explained as a chance finding, but could also be the result of lack of power, as also suggested by Brown et al. (<xref ref-type="bibr" rid="CR1">2004</xref>).</p><p>Despite the small numbers on which the analyses are based, the possible interactions between the <italic>NOS3</italic> 894GT/TT genotype and the <italic>MTHFR</italic> 677TT genotype or elevated plasma homocysteine concentrations are interesting and may suggest a role for NOS3 uncoupling or S-nitrosation. The <italic>NOS3</italic> 894G&#x0003e;T SNP (Glu298Asp) has been suggested to impair NOS3 protein function and/or activity resulting in decreased NO production (Sofowora et al. <xref ref-type="bibr" rid="CR13">2001</xref>; Tesauro et al. <xref ref-type="bibr" rid="CR17">2000</xref>), although results are contradictory (Fairchild et al. <xref ref-type="bibr" rid="CR5">2001</xref>). Elevated homocysteine concentrations have been demonstrated to switch the NOS3 enzyme to an uncoupled state directed to the synthesis of reactive oxygen species (ROS) rather than NO synthesis (Topal et al. <xref ref-type="bibr" rid="CR18">2004</xref>). The combination of the <italic>NOS3</italic> 894GT/TT genotype and elevated plasma homocysteine concentrations may lead to such a decrease in NO levels that neurulation is hampered. NO can also react with homocysteine to form <italic>S</italic>-nitrosothiols, thereby modulating homocysteine availability (Stamler et al. <xref ref-type="bibr" rid="CR15">1993</xref>). As previously suggested by our group (Heil et al. <xref ref-type="bibr" rid="CR6">2004</xref>), decreased NO levels may result in decreased <italic>S</italic>-nitrosothiol formation, resulting in less capturing of homocysteine into <italic>S</italic>-nitrosoHcy. The subsequent increase in plasma homocysteine concentrations might influence proper neural tube closure, especially when plasma homocysteine concentrations are already high.</p><p>The results of our study suggest that the <italic>NOS3</italic> 894G&#x0003e;T SNP is a spina bifida risk factor in the mother and not in the child. Our results furthermore indicate a role for the homocysteine metabolism in the detrimental effects asserted by the <italic>NOS3</italic> 894G&#x0003e;T SNP. More studies on the association between the <italic>NOS3</italic> 894G&#x0003e;T SNP and spina bifida in larger populations are warranted.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by the Prinses Beatrix Fonds, The Netherlands (MAR04-0121), the Dutch Kidney Foundation (C042083) and the NIH (1 R01 NS050249-01A1). Martin den Heijer is supported by The Netherlands Organization for Scientific Research (VENI grant NWO).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Kluijtmans</surname><given-names>LA</given-names></name><name><surname>Young</surname><given-names>IS</given-names></name><name><surname>Woodside</surname><given-names>J</given-names></name><name><surname>Yarnell</surname><given-names>JW</given-names></name><name><surname>McMaster</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>AE</given-names></name><name><surname>Boreham</surname><given-names>CA</given-names></name><name><surname>McNulty</surname><given-names>H</given-names></name><name><surname>Strain</surname><given-names>JJ</given-names></name><name><surname>Mitchell</surname><given-names>LE</given-names></name><name><surname>Whitehead</surname><given-names>AS</given-names></name></person-group><article-title>Genetic evidence that nitric oxide modulates homocysteine: the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>1014</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000071348.70527.F4</pub-id></citation><citation citation-type="display-unstructured">Brown KS, Kluijtmans LA, Young IS, Woodside J, Yarnell JW, McMaster D, Murray L, Evans AE, Boreham CA, McNulty H, Strain JJ, Mitchell LE, Whitehead AS (2003) Genetic evidence that nitric oxide modulates homocysteine: the NOS3 894TT genotype is a risk factor for hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 23:1014&#x02013;1020 <pub-id pub-id-type="pmid">12689917</pub-id></citation></ref><ref id="CR2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Cook</surname><given-names>M</given-names></name><name><surname>Hoess</surname><given-names>K</given-names></name><name><surname>Whitehead</surname><given-names>AS</given-names></name><name><surname>Mitchell</surname><given-names>LE</given-names></name></person-group><article-title>Evidence that the risk of spina bifida is influenced by genetic variation at the NOS3 locus</article-title><source>Birth Defects Res Part A Clin Mol Teratol</source><year>2004</year><volume>70</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1002/bdra.20002</pub-id></citation><citation citation-type="display-unstructured">Brown KS, Cook M, Hoess K, Whitehead AS, Mitchell LE (2004) Evidence that the risk of spina bifida is influenced by genetic variation at the NOS3 locus. Birth Defects Res Part A Clin Mol Teratol 70:101&#x02013;106 <pub-id pub-id-type="pmid">15039923</pub-id></citation></ref><ref id="CR3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danishpajooh</surname><given-names>IO</given-names></name><name><surname>Gudi</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kharitonov</surname><given-names>VG</given-names></name><name><surname>Sharma</surname><given-names>VS</given-names></name><name><surname>Boss</surname><given-names>GR</given-names></name></person-group><article-title>Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>27296</fpage><lpage>27303</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104043200</pub-id></citation><citation citation-type="display-unstructured">Danishpajooh IO, Gudi T, Chen Y, Kharitonov VG, Sharma VS, Boss GR (2001) Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway. J Biol Chem 276:27296&#x02013;27303 <pub-id pub-id-type="pmid">11371572</pub-id></citation></ref><ref id="CR4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heijer</surname><given-names>M</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name><name><surname>Gerrits</surname><given-names>WB</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Haak</surname><given-names>HL</given-names></name><name><surname>Wijermans</surname><given-names>PW</given-names></name><name><surname>Bos</surname><given-names>GM</given-names></name></person-group><article-title>Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>882</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(95)90008-X</pub-id></citation><citation citation-type="display-unstructured">den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, Bos GM (1995) Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 345:882&#x02013;885 <pub-id pub-id-type="pmid">7707810</pub-id></citation></ref><ref id="CR5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairchild</surname><given-names>TA</given-names></name><name><surname>Fulton</surname><given-names>D</given-names></name><name><surname>Fontana</surname><given-names>JT</given-names></name><name><surname>Gratton</surname><given-names>JP</given-names></name><name><surname>McCabe</surname><given-names>TJ</given-names></name><name><surname>Sessa</surname><given-names>WC</given-names></name></person-group><article-title>Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)-&#x0003e;Asp variant of human endothelial nitric-oxide synthase</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>26674</fpage><lpage>26679</lpage><pub-id pub-id-type="doi">10.1074/jbc.M103647200</pub-id></citation><citation citation-type="display-unstructured">Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC (2001) Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)-&#x0003e;Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 276:26674&#x02013;26679 <pub-id pub-id-type="pmid">11331296</pub-id></citation></ref><ref id="CR6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heil</surname><given-names>SG</given-names></name><name><surname>Heijer</surname><given-names>M</given-names></name><name><surname>Rijt-Pisa</surname><given-names>BJ</given-names></name><name><surname>Kluijtmans</surname><given-names>LA</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>The 894G&#x0003e;T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels</article-title><source>J Thromb Haemost</source><year>2004</year><volume>2</volume><fpage>750</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00701.x</pub-id></citation><citation citation-type="display-unstructured">Heil SG, den Heijer M, Van Der Rijt-Pisa BJ, Kluijtmans LA, Blom HJ (2004) The 894G&#x0003e;T variant of endothelial nitric oxide synthase (eNOS) increases the risk of recurrent venous thrombosis through interaction with elevated homocysteine levels. J Thromb Haemost 2:750&#x02013;753 <pub-id pub-id-type="pmid">15099281</pub-id></citation></ref><ref id="CR7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Liang</surname><given-names>CF</given-names></name><name><surname>Fatibene</surname><given-names>J</given-names></name><name><surname>Lyon</surname><given-names>A</given-names></name><name><surname>Monteith</surname><given-names>S</given-names></name><name><surname>Parsons</surname><given-names>A</given-names></name><name><surname>Haydock</surname><given-names>S</given-names></name><name><surname>Hopper</surname><given-names>RV</given-names></name><name><surname>Stephens</surname><given-names>NG</given-names></name><name><surname>O&#x02019;Shaughnessy</surname><given-names>KM</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name></person-group><article-title>A common variant of the endothelial nitric oxide synthase (Glu298-&#x0003e;Asp) is a major risk factor for coronary artery disease in the UK</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>1515</fpage><lpage>1520</lpage></citation><citation citation-type="display-unstructured">Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S, Hopper RV, Stephens NG, O&#x02019;Shaughnessy KM, Brown MJ (1999) A common variant of the endothelial nitric oxide synthase (Glu298-&#x0003e;Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100:1515&#x02013;1520 <pub-id pub-id-type="pmid">10510054</pub-id></citation></ref><ref id="CR8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>QP</given-names></name><name><surname>Juchau</surname><given-names>MR</given-names></name></person-group><article-title>Dysmorphogenic effects of nitric oxide (NO) and NO-synthase inhibition: studies with intra-amniotic injections of sodium nitroprusside and NG-monomethyl-<sc>l</sc>-arginine</article-title><source>Teratology</source><year>1994</year><volume>49</volume><fpage>452</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/tera.1420490605</pub-id></citation><citation citation-type="display-unstructured">Lee QP, Juchau MR (1994) Dysmorphogenic effects of nitric oxide (NO) and NO-synthase inhibition: studies with intra-amniotic injections of sodium nitroprusside and NG-monomethyl-l-arginine. Teratology 49:452&#x02013;464 <pub-id pub-id-type="pmid">7538231</pub-id></citation></ref><ref id="CR9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>F</given-names></name></person-group><article-title>Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>2003</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa063904</pub-id></citation><citation citation-type="display-unstructured">Murad F (2006) Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 355:2003&#x02013;2011 <pub-id pub-id-type="pmid">17093251</pub-id></citation></ref><ref id="CR10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nachmany</surname><given-names>A</given-names></name><name><surname>Gold</surname><given-names>V</given-names></name><name><surname>Tsur</surname><given-names>A</given-names></name><name><surname>Arad</surname><given-names>D</given-names></name><name><surname>Weil</surname><given-names>M</given-names></name></person-group><article-title>Neural tube closure depends on nitric oxide synthase activity</article-title><source>J Neurochem</source><year>2006</year><volume>96</volume><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03542.x</pub-id></citation><citation citation-type="display-unstructured">Nachmany A, Gold V, Tsur A, Arad D, Weil M (2006) Neural tube closure depends on nitric oxide synthase activity. J Neurochem 96:247&#x02013;253 <pub-id pub-id-type="pmid">16300634</pub-id></citation></ref><ref id="CR11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plachta</surname><given-names>N</given-names></name><name><surname>Traister</surname><given-names>A</given-names></name><name><surname>Weil</surname><given-names>M</given-names></name></person-group><article-title>Nitric oxide is involved in establishing the balance between cell cycle progression and cell death in the developing neural tube</article-title><source>Exp Cell Res</source><year>2003</year><volume>288</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/S0014-4827(03)00215-5</pub-id></citation><citation citation-type="display-unstructured">Plachta N, Traister A, Weil M (2003) Nitric oxide is involved in establishing the balance between cell cycle progression and cell death in the developing neural tube. Exp Cell Res 288:354&#x02013;362 <pub-id pub-id-type="pmid">12915126</pub-id></citation></ref><ref id="CR12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><article-title>Genetic power calculator: design of linkage and association genetic mapping studies of complex traits</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/19.1.149</pub-id></citation><citation citation-type="display-unstructured">Purcell S, Cherny SS, Sham PC (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149&#x02013;150 <pub-id pub-id-type="pmid">12499305</pub-id></citation></ref><ref id="CR13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sofowora</surname><given-names>G</given-names></name><name><surname>Dishy</surname><given-names>V</given-names></name><name><surname>Xie</surname><given-names>HG</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Nishimi</surname><given-names>Y</given-names></name><name><surname>Morales</surname><given-names>CR</given-names></name><name><surname>Morrow</surname><given-names>JD</given-names></name><name><surname>Kim</surname><given-names>RB</given-names></name><name><surname>Stein</surname><given-names>CM</given-names></name><name><surname>Wood</surname><given-names>AJ</given-names></name></person-group><article-title>In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism</article-title><source>Pharmacogenetics</source><year>2001</year><volume>11</volume><fpage>809</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1097/00008571-200112000-00009</pub-id></citation><citation citation-type="display-unstructured">Sofowora G, Dishy V, Xie HG, Imamura H, Nishimi Y, Morales CR, Morrow JD, Kim RB, Stein CM, Wood AJ (2001) In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 11:809&#x02013;814 <pub-id pub-id-type="pmid">11740345</pub-id></citation></ref><ref id="CR14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spielman</surname><given-names>RS</given-names></name><name><surname>McGinnis</surname><given-names>RE</given-names></name><name><surname>Ewens</surname><given-names>WJ</given-names></name></person-group><article-title>Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM)</article-title><source>Am J Hum Genet</source><year>1993</year><volume>52</volume><fpage>506</fpage><lpage>516</lpage></citation><citation citation-type="display-unstructured">Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 52:506&#x02013;516 <pub-id pub-id-type="pmid">8447318</pub-id></citation></ref><ref id="CR15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stamler</surname><given-names>JS</given-names></name><name><surname>Osborne</surname><given-names>JA</given-names></name><name><surname>Jaraki</surname><given-names>O</given-names></name><name><surname>Rabbani</surname><given-names>LE</given-names></name><name><surname>Mullins</surname><given-names>M</given-names></name><name><surname>Singel</surname><given-names>D</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><article-title>Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>308</fpage><lpage>318</lpage></citation><citation citation-type="display-unstructured">Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J (1993) Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308&#x02013;318 <pub-id pub-id-type="pmid">8380812</pub-id></citation></ref><ref id="CR16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>te Poele-Pothoff</surname><given-names>MT</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Franken</surname><given-names>DG</given-names></name><name><surname>Boers</surname><given-names>GH</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name><name><surname>Kroon</surname><given-names>IF</given-names></name><name><surname>Eskes</surname><given-names>TK</given-names></name><name><surname>Trijbels</surname><given-names>JM</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Three different methods for the determination of total homocysteine in plasma.</article-title><source>Ann Clin Biochem</source><year>1995</year><volume>32</volume><fpage>218</fpage><lpage>220</lpage></citation><citation citation-type="display-unstructured">te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ (1995) Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 32:218&#x02013;220 <pub-id pub-id-type="pmid">7785955</pub-id></citation></ref><ref id="CR17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tesauro</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>WC</given-names></name><name><surname>Rogliani</surname><given-names>P</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Chaudhary</surname><given-names>PP</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name></person-group><article-title>Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>2832</fpage><lpage>2835</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.6.2832</pub-id></citation><citation citation-type="display-unstructured">Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J (2000) Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97:2832&#x02013;2835 <pub-id pub-id-type="pmid">10717002</pub-id></citation></ref><ref id="CR18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Topal</surname><given-names>G</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Millanvoye</surname><given-names>E</given-names></name><name><surname>Boucher</surname><given-names>JL</given-names></name><name><surname>Rendu</surname><given-names>F</given-names></name><name><surname>Devynck</surname><given-names>MA</given-names></name><name><surname>vid-Dufilho</surname><given-names>M</given-names></name></person-group><article-title>Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin</article-title><source>Free Radic Biol Med</source><year>2004</year><volume>36</volume><fpage>1532</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2004.03.019</pub-id></citation><citation citation-type="display-unstructured">Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, vid-Dufilho M (2004) Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36:1532&#x02013;1541 <pub-id pub-id-type="pmid">15182855</pub-id></citation></ref><ref id="CR19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traister</surname><given-names>A</given-names></name><name><surname>Abashidze</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>V</given-names></name><name><surname>Plachta</surname><given-names>N</given-names></name><name><surname>Karchovsky</surname><given-names>E</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Weil</surname><given-names>M</given-names></name></person-group><article-title>Evidence that nitric oxide regulates cell-cycle progression in the developing chick neuroepithelium</article-title><source>Dev Dyn</source><year>2002</year><volume>225</volume><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1002/dvdy.10164</pub-id></citation><citation citation-type="display-unstructured">Traister A, Abashidze S, Gold V, Plachta N, Karchovsky E, Patel K, Weil M (2002) Evidence that nitric oxide regulates cell-cycle progression in the developing chick neuroepithelium. Dev Dyn 225:271&#x02013;276 <pub-id pub-id-type="pmid">12412009</pub-id></citation></ref><ref id="CR20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beynum</surname><given-names>IM</given-names></name><name><surname>Smeitink</surname><given-names>JA</given-names></name><name><surname>Heijer</surname><given-names>M</given-names></name><name><surname>te Poele Pothoff</surname><given-names>MT</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>Hyperhomocysteinemia: a risk factor for ischemic stroke in children</article-title><source>Circulation</source><year>1999</year><volume>99</volume><fpage>2070</fpage><lpage>2072</lpage></citation><citation citation-type="display-unstructured">van Beynum IM, Smeitink JA, den Heijer M, te Poele Pothoff MT, Blom HJ (1999) Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation 99:2070&#x02013;2072 <pub-id pub-id-type="pmid">10217643</pub-id></citation></ref><ref id="CR21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname><given-names>IJ</given-names></name><name><surname>Heijer</surname><given-names>M</given-names></name><name><surname>Afman</surname><given-names>LA</given-names></name><name><surname>Gellekink</surname><given-names>H</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Kluijtmans</surname><given-names>LA</given-names></name><name><surname>Blom</surname><given-names>HJ</given-names></name></person-group><article-title>The methionine synthase reductase 66A&#x0003e;G polymorphism is a maternal risk factor for spina bifida</article-title><source>J Mol Med</source><year>2006</year><volume>84</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1007/s00109-006-0093-x</pub-id></citation><citation citation-type="display-unstructured">van der Linden IJ, Den Heijer M, Afman LA, Gellekink H, Vermeulen SH, Kluijtmans LA, Blom HJ (2006) The methionine synthase reductase 66A&#x0003e;G polymorphism is a maternal risk factor for spina bifida. J Mol Med 84:1047&#x02013;1054 <pub-id pub-id-type="pmid">17024475</pub-id></citation></ref><ref id="CR22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weil</surname><given-names>M</given-names></name><name><surname>Abeles</surname><given-names>R</given-names></name><name><surname>Nachmany</surname><given-names>A</given-names></name><name><surname>Gold</surname><given-names>V</given-names></name><name><surname>Michael</surname><given-names>E</given-names></name></person-group><article-title>Folic acid rescues nitric oxide-induced neural tube closure defects</article-title><source>Cell Death Differ</source><year>2004</year><volume>11</volume><fpage>361</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401371</pub-id></citation><citation citation-type="display-unstructured">Weil M, Abeles R, Nachmany A, Gold V, Michael E (2004) Folic acid rescues nitric oxide-induced neural tube closure defects. Cell Death Differ 11:361&#x02013;363 <pub-id pub-id-type="pmid">14685162</pub-id></citation></ref></ref-list></back></article> 